Chylothorax Under Dasatinib in a Child with Chronic Myeloid Leukemia

Xuan F, Zhang B, Zhao X and Wu X*

Department of Children’s Hematologic Oncology Center, The Second Hospital of Hebei Medical University, China

^*Correspondance to: Xiaoli Wu 

 PDF  Full Text Case Report | Open Access

Abstract:

A 12-year-old girl was admitted to our hospital for hepatosplenomegaly. She was diagnosed with chronic myeloid leukemia more than 8 years ago. Imatinib was administered orally for 5 years; however, an increase was noted in BCR-ABL1 fusion gene levels and the treatment drug was changed to dasatinib. The BCR-ABL1 fusion gene levels gradually decreased and stabilized; therefore, dasatinib treatment was continued. After 3 years on oral dasatinib therapy, she developed hepatosplenomegaly and chylothorax. After repeated examinations to rule out other causes, dasatinib was discontinued and replaced with nilotinib. Thereafter, the pleural effusion completely resolved, the liver and spleen size normalized and the primary disease was controlled and stabilized.

Keywords:

Chronic myeloid leukemia; Dasatinib; Chylothorax; Children

Cite the Article:

Xuan F, Zhang B, Zhao X, Wu X. Chylothorax Under Dasatinib in a Child with Chronic Myeloid Leukemia. Ann Clin Case Rep. 2023; 8: 2418.